{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:29Z","timestamp":1793600909093,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.02.5092","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:08:07Z","timestamp":1774534087000},"page":"1157-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement"],"prefix":"10.1016","volume":"88","author":[{"given":"Amrut V.","family":"Ambardekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Musunuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.02.5092_bib2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/genetics\/161.3.1169","article-title":"Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases","volume":"161","author":"Bibikova","year":"2002","journal-title":"Genetics"},{"key":"10.1016\/j.jacc.2026.02.5092_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jacc.2026.02.5092_bib4","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2026.02.5092_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2026.02.5092_bib6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.02.5092_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.02.5092_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.02.5092_bib9","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nu\u00f1ez","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2026.02.5092_bib10","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib11","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41586-025-09732-2","article-title":"Prime editing-installed suppressor tRNAs for disease-agnostic genome editing","volume":"648","author":"Pierce","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.02.5092_bib16","doi-asserted-by":"crossref","first-page":"A4139206","DOI":"10.1161\/circ.150.suppl_1.4139206","article-title":"Abstract 4139206: Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol","volume":"150","author":"Vafai","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5092_bib18","article-title":"Abstract 17013: CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein (a) levels in non-human primates after a single dose","volume":"148","author":"Morrow","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5092_bib22","author":"Liang"},{"key":"10.1016\/j.jacc.2026.02.5092_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202412335","article-title":"Innovation of lipid-based nanoparticles: the design and applications in the cardiovascular disease management","volume":"35","author":"Gu","year":"2025","journal-title":"Adv Funct Mater"},{"issue":"5","key":"10.1016\/j.jacc.2026.02.5092_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib25","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1073\/pnas.90.6.2375","article-title":"Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone","volume":"90","author":"Episkopou","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2026.02.5092_bib26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1074\/jbc.270.2.866","article-title":"Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination","volume":"270","author":"Wei","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2026.02.5092_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.55.5.767","article-title":"HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study","volume":"55","author":"Castelli","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5092_bib32","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1126\/science.185.4145.61","article-title":"Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man","volume":"185","author":"Brown","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.jacc.2026.02.5092_bib34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib35","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5092_bib36","article-title":"Base editing gene therapy for heterozygous familial Hypercholesterolemia","author":"Wan","year":"2025","journal-title":"Medrxiv"},{"key":"10.1016\/j.jacc.2026.02.5092_bib37","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib39","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib40","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2026.02.5092_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib49","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.02.5092_bib50","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2026.02.5092_bib51","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib52","article-title":"Day 1 at ASGCT: missing scientists, a gene editing failure, and a gene editing first","author":"Mast","year":"2025","journal-title":"STAT"},{"key":"10.1016\/j.jacc.2026.02.5092_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically modified porcine-to-human cardiac xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N Engl J Med"},{"issue":"Pt B","key":"10.1016\/j.jacc.2026.02.5092_bib55","first-page":"161","article-title":"Biochemical genetics of LDL receptor mutations in familial hypercholesterolemia","volume":"103","author":"Goldstein","year":"1982","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.jacc.2026.02.5092_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2026.02.5092_bib57","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5092_bib58","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","author":"Lahuerta Pueyo","year":"2019","journal-title":"Eur J Hum Genet EJHG"},{"key":"10.1016\/j.jacc.2026.02.5092_bib60","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41436-020-0876-4","article-title":"Clinical outcomes of a genomic screening program for actionable genetic conditions","volume":"22","author":"Buchanan","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib61","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/eurheartj\/ehac009","article-title":"PDAY risk score predicts cardiovascular events in young adults: the CARDIA study","volume":"43","author":"Gidding","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.02.5092_bib62","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/europace\/euac030","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases","volume":"24","author":"Wilde","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2026.02.5092_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000086","article-title":"Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the American Heart Association","volume":"14","author":"Landstrom","year":"2021","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000067","article-title":"Genetic testing for inherited cardiovascular diseases: a scientific statement From the American Heart Association","volume":"13","author":"Musunuru","year":"2020","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib65","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1272433","article-title":"Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases","volume":"10","author":"Longoni","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.122.004028","article-title":"Real-world genetic testing utilization among patients with cardiomyopathy","volume":"17","author":"Morales","year":"2024","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib68","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41436-018-0311-2","article-title":"Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia","volume":"21","author":"Alver","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib69","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13073-021-00832-y","article-title":"Implementing genomic screening in diverse populations","volume":"13","author":"Abul-Husn","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0917","article-title":"Genomic screening at a single health system","volume":"8","author":"Savatt","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.02.5092_bib72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib74","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib75","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physiolgenomics.00025.2021","article-title":"Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review","volume":"53","author":"Elfatih","year":"2021","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jacc.2026.02.5092_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.125.005078","article-title":"Implementing precision medicine for dilated cardiomyopathy: insights from the DCM consortium","volume":"18","author":"Jordan","year":"2025","journal-title":"Circ Genomic Precis Med"},{"key":"10.1016\/j.jacc.2026.02.5092_bib78","series-title":"Engineering, and Medicine, National Academy of Medicine, National Academy of Sciences, Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations. Human Genome Editing: Science, Ethics, and Governance","year":"2017"},{"key":"10.1016\/j.jacc.2026.02.5092_bib79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jacc.2026.02.5092_bib80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-med-112717-094629","article-title":"Ethics of human genome editing","volume":"70","author":"Coller","year":"2019","journal-title":"Annu Rev Med"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2026.06.034","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000}}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726055609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726055609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:48:47Z","timestamp":1793598527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726055609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726055609"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5092","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}